Samsung Biologics Contract Manufacturing

Samsung Biologics operates the world's largest single-site biopharmaceutical manufacturing complex in Songdo, Incheon, with Plants 1-4 providing 604,000 liters of mammalian cell culture capacity and Plant 5 (under construction) adding another 180,000L. In H1 2025, the company reported $1.88B revenue and signed a landmark $897M contract with Pfizer for antibody drug manufacturing.

The CDMO (Contract Development and Manufacturing Organization) model means Samsung Biologics manufactures biologic drugs — antibodies, vaccines, cell therapies — on behalf of global pharmaceutical companies. Its competitive advantages are Samsung-grade manufacturing reliability, unprecedented scale, and the ability to bring new capacity online faster than Western competitors like Lonza, Boehringer Ingelheim, or WuXi Biologics.

Samsung Biologics exemplifies the Korean innovation playbook applied to biotech: identify a high-value manufacturing niche, invest massively in capacity and quality systems, and execute at a scale that creates a natural moat. The company is now expanding into antibody-drug conjugates (ADCs), mRNA manufacturing, and cell/gene therapy production, aiming to become a full-service biologic drug development partner.